July 23, 2022, during the 19th Congress of Cardiac Imaging and Cardiac Intervention (CICI 2022) and the 2022 China Cardiovascular Forum , “3F FORYOU MicroPortCoronary”, a subsidiary of MicroPort Medical Science Co., Ltd. (00853.HK), Shanghai MicroPort Medical (Group) Co., Ltd. sup>®Coronary and Coronary Heart Disease Complete Solution Medical Solution-Precision PCI Symposium” was grandly held. This conference specially invited well-known experts in the field of coronary intervention from all over the country to gather in the cloud to focus on the minimally invasive ®Discuss the innovative products independently developed, aiming to appreciate the original power of China and demonstrate the stunning charm of domestic original equipment!
The PLA General Hospital of the People’s Liberation Army is specially invited for this seminar span>Professor Chen Yundaias the guest chair; Fuwai Hospital, Chinese Academy of Medical SciencesProfessor Dou Kefei strong>, Jiangxi Provincial People’s HospitalProfessor Hong Lang, Peking University No. 1 HospitalProfessor Li Jianping, Shanghai Oriental HospitalZhang Prof. Qi served as the host; hosted by Fuwai Hospital, Chinese Academy of Medical SciencesProfessor Xu Bo strong>, The Second Affiliated Hospital of Harbin Medical UniversityProfessor Jingbo Hou, China People’s Liberation Army General HospitalProfessor Jin Qinhua brought wonderful academic sharing. (in order of lectures)
Opening remarks
3F FOR YOU Minimally Invasive ®Coronary Coronary Heart Disease Total Solution Medical Solution
At the beginning of the conference, Professor Chen Yundai said that in the past two decades, my country has made a The technology and technology are constantly evolving and improving, and the domestic original research equipment has made great progress. Many domestic medical enterprises have not forgotten their original aspirations and kept their mission in mind, and continue to innovate and progress for the benefit of Chinese patients. It is precisely in order to allow more practitioners in the field of coronary intervention to see the strength of domestic production, this symposium specially invited well-known domestic experts in the field of coronary intervention to focus on the bioabsorbable Firesorb® independently developed by MicroPort. Stents, Minimally Invasive Argus™ OCT System, SoulMan Minokawong Medical Vascular X-ray Machine and the domestic original research equipment were discussed brilliantly.
Professor Xu Bo: Bioresorbable scaffold “Fire ibis ®“ span>
FUTURE series research progress
3F FOR YOU Minimally Invasive< sup>®Coronary Coronary Heart Disease Total Solution Medical Solution
®Fire is Micro-Invasive A bioabsorbable stent with thinner stent beams and covered with sirolimus was developed.Professor Xu BoReproduce the unique advantages of Firesorb® BRS in combination with the latest research progress of FUTURE series. The FUTURE-I study, as a FIM study using Firesorb® BRS, preliminarily proved the feasibility and safety of Firesorb® BRS. followed byThe one-year follow-up results of the prospective, multicenter, randomized controlled trial FUTURE-II showed that the Firesorb® BRS stent had no significant effect on late lumen loss and stent beam coverage. Inferior to control stents and did not find any late stent beam disruption or lumen collapse. The 2-year follow-up results of the much-received FUTURE-II study have also been officially announced. The excellent study results once again confirmed the safety of the new generation of thin-walled Firesorb® BRS stents Sexuality and effectiveness. The 2-year follow-up results of the FUTURE-II study showed that the incidence of target lesion failure (TLF) in patients with Firesorb® BRS stent implantation was 3.8%, PoCE (all-cause death, all myocardial infarction or any blood supply) The incidence of reconstruction) was 11.3%, which was non-inferior to the control stent group (Fig. 1), and there was no significant difference in each composite endpoint, especially in terms of safety indicators, patients implanted with Firesorb® BRS stent showed a trend toward lower rates of cardiac death and device-related thrombotic events (Figure 2).
Figure 1: 2-year follow-up results of the FUTURE-II study
Figure 2: 2-year composite endpoint results of the FUTURE-II study
Landmark The results of the analysis showed that the increase in the incidence of PoCE occurred mainly between 1 year and 16 months after surgery in both groups (Figure 3).
Figure 3: Landmark analysis results
span>In addition, the researchers also explored subgroup analysis, grouping the enrolled patients according to the size of the vessel diameter. The results showed that there was no significant difference in the stent beam coverage rate at 1 year after surgery and the incidence of TLF events at 2 years after surgery between the Firesorb® BRS stent group and the control stent group. The proportion of late lumen loss after implantation of the Firesorb® BRS stent was slightly higher in middle-stage patients, which needs to be systematically verified in the future. (Figure 4).
Figure 4: Subgroup analysis results
In conclusion, the results of the FUTURE-II study showed that the Firesorb® BRS stent was non-inferior to the control stent in terms of the primary end point of late loss and the secondary end point of stent beam coverage. And the two-year incidence of adverse clinical events including TLF, PoCE and stent thrombosis continued to be low, confirming that Firesorb® BRS stent can be used for the treatment of uncomplicated primary coronary lesions , providing a chance to make a comeback for bioabsorbable stents with PLLA as the main body of the stent! Now that the FUTURE-III study has also completed the enrolment work, we look forward to the publication of the research results to bring new inspiration to more experts and scholars in the industry!
Expert Comments
Professor Dou Kefei:< /span>Through the results of the FUTURE series, it can be found that the Firesorb® BRS stent is superior in terms of late lumen loss, complete protrusion of the vessel wall or composite endpoints. They are not inferior to or even superior to mainstream drug-eluting stents. Although the current indication for implantation of this stent is only for uncomplicated coronary artery disease, as Professor Xu Bo said, Firesorb® BRS The stent has the ability to treat complex coronary lesions. It is believed that with the publication of more evidence-based evidence, the Firesorb® BRS stent will be approved for the treatment of patients with complex coronary lesions in the near future. We look forward to the launch of the Firesorb® BRS stent as soon as possible!
Professor Hou Jingbo: Micro-tracking Light Mirror, Extraordinarily Accurate
Introduction to Minimally Invasive Argus™ OCT
3F FOR YOU Minimally Invasive ® sup>Coronary Coronary Heart Disease Total Solution Medical Solution
The advent of the era of non-implantation intervention, the widespread application of DCB, especially the re-understanding and re-application of bioabsorbable stents, OCT has become a coronary intervention therapy Professor Jingbo Hou elaborated on the Minimally Invasive Argus™ Features of the OCT system.The minimally invasive Argus™ OCT system consists of the ArgusClarity® OCT imaging system and the NOPURGE® imaging catheter. NOPURGE ®The imaging catheter adopts patented technology, simple structure, no Luer port at the proximal end, and fully closed at the distal end, plug and play, no need to rinse the distal lens, the lens does not contact blood, avoids damage to the lens by the guide wire, reduces the The use of contrast media simplifies the surgical procedure, especially when multiple withdrawals are required, greatly shortens the operation time, solves all the clinical problems caused by flushing the lumen, and the imaging quality is consistent with foreign OCT products. NOPURGE® The proximal end of the imaging catheter core is an optical fiber connector, and the distal end is an optical fiber lens. The integrated design of the optical fiber without solder joints makes the imaging catheter have good anti-breakage and bending ability, which can reduce the occurrence of catheter fracture; the front end of the imaging catheter Covered with Surskin hydrophilic coating, which can reduce the friction between the imaging catheter and the blood vessel after activation with heparin saline, and improve the passage and pushability of the catheter in the blood vessel. The smallest outer diameter of the distal end of the imaging catheter and tip-lens The distance can help the catheter to reach stenosis, smaller diameter and further vascular segments, and can provide intravascular imaging information of the distal longer segment. The NOPURGE® imaging catheter has 3 imaging rings at the front end, The distal end of the catheter, the position of the lens, and the proximal end of the catheter are respectively marked, and a reference scale for real-time evaluation of the scanning range is provided. The 1-meter mark in the middle of the catheter can feedback the length of the catheter in the patient’s body. When advancing and retreating the imaging catheter, the operator will be reminded to control Speed and strength. The ArgusClarity® imaging system achieves quantum limit low-noise light transmission through patented technology, making the OCT detection image clearer and reaching the same level as imported brands. ArgusClarity® OCT The wider range of scanning in blood vessels makes it possible to explore blood vessels with larger diameters; ArgusClarity® has a high resolution rate of 10 μm, and in the scanning range of 2.0 mm-3.5 mm, the image The branch office rate can reach the same level as imported brands.In general, the minimally invasive Argus™ OCT system has excellent features such as clear visibility, clear identification, accurate matching, no flushing, easy passage, and good positioning. Compared with other brands of OCT, the relative error level of the clear stent length in the Minimally Invasive Argus™ OCT group did not exceed ±10%, the measurement performance of the two was comparable, and the main evaluation index of effectiveness reached expectations, and there was no related test equipment during the test. of adverse events and serious adverse events, the safety of Minimally Invasive Argus™ OCT products is guaranteed!
Results
Expert Reviews
< strong>Professor Hong Lang:In recent years, IVUS and OCT, as the current mainstream endoluminal imaging techniques, play an important role in the treatment of patients with complex coronary artery disease Role, compared with IVUS, OCT has higher imaging resolution, can provide more accurate and comprehensive culprit vessel information, and is useful in evaluating vulnerable plaques and guiding stent placement, especially in the diagnosis and treatment of ACS and severe calcified lesions. It has unique advantages, and the MicroPort Argus™ OCT independently developed by MicroPort is equipped with a no-irrigation function, which solves all the clinical problems caused by the flushing of the lumen, successfully reduces the use of contrast agents, simplifies the surgical procedure, and greatly shortens the operation. Time, I think this improvement will benefit more patients with renal insufficiency or allergies to contrast media!
Professor Jin Qinhua: Traces of Minimally Invasive Soul-Man
< span>Introduction of Medical Vascular X-ray Machine
3F FOR YOU Minimally Invasive ®Coronary Coronary Heart Disease Total Solution Medical Scheme
Finally, Professor Jinqinhua strong>Introduced the features and applications of the first domestic high-end DSA independently developed by MicroPort to the participating experts. As MicroPort’s first domestic high-end angiography system, Soul-Man is a user-centered, user-friendly DSA general-purpose machine with high practicability and high availability, covering an area of only 25m² ( Image 6). Soul-Man Minotaur uses a dedicated low-dose collection protocol that reduces radiation dose by 67% compared to standard collection protocols, making it more caring for children, low-weight adults and other dose-sensitive patients. Soul-Man has the function of real-time precise display of stents. Without waiting, high-definition images of stents can be obtained synchronously on the screen, which can be highlighted in real time, and the position of stents can be fixed in real time in the center of the screen. Contrast agent usage. Soul-Man covers all standard coronary angiography angles in one runEvaluation of coronary vessels, Automap function can automatically freeze lesions at the ideal viewing angle; QCA quantitative coronary angiography function can be automatically or manually calibrated, automatic vessel contour recognition, automatic detection of stenosis degree and reference diameter, and stenosis calculation by geometry and density . SyngoIZ 3D mode can automatically create 3D VRT images of single and bifurcated coronary arteries in the region of interest using 2 contrast images with different projection angles, and use interactive coronary 3D VRT images to easily visualize, quantify and evaluate vascular anatomy, Eliminating the errors of out-of-plane enlargement and shortening, virtual stent technology guides stent size selection and stent positioning and release; dual-volume reconstruction technology can not only display three-dimensional vascular images and the brain containing therapeutic materials in one image, but also Separating them shows that this has a very positive significance for the establishment of interventional treatment plans, postoperative evaluation and even surgical treatment.
 and the 2022 Huaxia Cardiovascular Disease The forum has ended successfully. Many domestic experts in the field of cardiovascular disease gathered online to discuss the current new technologies, new concepts and new progress in the field of cardiovascular disease, presenting a hearty academic feast for all the audience. </span><span>In the future, MicroPort® <sup>®</sup> Coronary Artery will continue to help disseminate cutting-edge academic information, share clinical experience, promote academic exchanges in the field of cardiovascular disease, and provide patients with more long-term benefits. And life-shaping coronary heart disease comprehensive medical solutions. </span></p><p><img decoding=)
The content of this article is original content of “Outpatient” magazine
Reprinted with permission and please indicate the source.
New Vision for Clinic Clinic span>｜WeChat: ClinicMZ
Long press, identify the QR code, and follow